Research LettersPrognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia
References (5)
- et al.
Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group
Blood
(1991) - et al.
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
Lancet
(1998)
There are more references available in the full text version of this article.
Cited by (192)
Advanced Minimal Residual Disease Monitoring for Acute Lymphoblastic Leukemia with Multiplex Mediator Probe PCR
2022, Journal of Molecular DiagnosticsOutcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
2019, The Lancet HaematologyCitation Excerpt :Irrespective of treatment strategies, children relapsing more than 6 months after stopping therapy have better survival rates than those who relapse earlier (overall survival 45–73% for those who relapse >6 months later vs 22–38% for those who relapse earlier),1–4 suggesting that recurring blasts remain chemosensitive in many patients. The BFM Study Group identified a subset of patients with late bone marrow relapses (isolated or combined) who had low minimal residual disease (defined as <10−3 cells) at end of induction and could thus be maintained in second complete remission with chemotherapy and targeted radiotherapy.5 Those with minimal residual disease comprising 10−3 cells or more, however, frequently had a second relapse.
How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
2017, Best Practice and Research: Clinical HaematologyRelapsed Acute Lymphoblastic Leukemia
2024, Indian Journal of Pediatrics
Copyright © 2001 Elsevier Ltd. All rights reserved.